Treatments for cancer, cholesterol and chronic migraines among medicines accepted for routine use by NHS Scotland

The Scottish Medicines Consortium (SMC) has accepted six new medicines for routine use by NHS Scotland. Osimertinib (Tagrisso) was accepted for the treatment of non-small cell lung cancer following consideration through the SMC’s Patient and Clinician Engagement (PACE) process for medicines used to treat end of life and very rare conditions. The PACE meeting heard that osimertinib is better tolerated than other current treatments and is taken orally, factors that can allow patients to lead more normal lives and possibly return to work. Also accepted through the PACE process was Everolimus (Afinitor), which is used for the treatment of a